AvenCell raised $112 million in a Series B funding round led by Novo Holdings to accelerate clinical validation of its proprietary Universal Switchable CAR-T cell therapy platform.

Oct 22, 2024•about 1 year ago

Amount Raised

$112 Million

Round Type

series b

CambridgeTherapeuticsMedicalBiotechnologyHealth Care

Investors

Blackstone Life SciencesNybc VenturesPiper Heartland Healthcare CapitalEight Roads Ventures JapanF Prime CapitalNovo Holdings

Description

AvenCell Therapeutics, Inc. has successfully raised $112 million in its Series B financing round. The funding, led by Novo Holdings and joined by new investors such as F-Prime Capital and Eight Roads Ventures Japan, will support the clinical development of its innovative CAR-T cell therapy platform.

Company Information

Company

AvenCell Therapeutics

Location

Cambridge, Massachusetts, United States

About

AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies. Their proprietary Universal Switchable CAR-T cell therapy platform is designed to treat various hematologic malignancies and autoimmune diseases. AvenCell aims to transform the standard of care with innovative and adaptable cell therapy treatments. The company has several pipeline candidates in clinical trials addressing high unmet medical needs.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends